Europe Hereditary Cancer Testing Market – Industry Trends and Forecast to 2029

Analyse et perspectives du marché européen des tests de dépistage du cancer héréditaire

Le cancer est une maladie génétique causée par certaines mutations dans les gènes qui contrôlent la fonction des cellules, affectant notamment leur croissance et leur reproduction. Les mutations génétiques héréditaires sont responsables d'environ 5 à 10 % de tous les cancers. Les chercheurs ont lié les mutations de gènes spécifiques à plus de 50 syndromes cancéreux héréditaires qui affectent les personnes par le biais du développement de certains cancers. En outre, environ 5 à 10 % des cas de cancer du sein sont associés à des mutations génétiques héritées des parents. Ainsi, la prévalence croissante du cancer entraîne une croissance constante des cancers héréditaires et, par conséquent, la croissance du marché des tests de cancer héréditaire. En outre, la demande accrue de méthodes de test non invasives et la demande croissante de soins de santé de meilleure qualité et de diagnostic précoce sont les principales opportunités de croissance du marché. De plus, les défis éthiques rencontrés lors des tests de cancer héréditaire et la concurrence croissante entre les acteurs du marché sont les principaux défis pour la croissance du marché.

Toutefois, les réglementations strictes en matière de diagnostic du cancer et le coût élevé associé aux tests peuvent entraver la croissance du marché.

Data Bridge Market Research estime que le marché européen des tests de dépistage du cancer héréditaire devrait atteindre la valeur de 4 289,12 millions USD d'ici 2029, à un TCAC de 12,4 % au cours de la période de prévision. Ce rapport de marché couvre également en profondeur l'analyse des prix, l'analyse des brevets et les avancées technologiques.

Définition du marché européen des tests de dépistage du cancer héréditaire

Le cancer héréditaire est un cancer causé par une mutation génétique héréditaire. Des variantes nocives dans certains gènes sont associées à un risque accru de cancer. Les tests génétiques peuvent estimer le risque de développer un cancer au cours de la vie d'une personne. Cela peut être fait en recherchant des mutations dans leurs gènes, leurs chromosomes ou leurs protéines. Des tests génétiques sont disponibles pour plusieurs types de cancer. Il s'agit notamment du cancer du sein, de l'ovaire, du côlon, de la thyroïde, de la prostate, du pancréas, de la peau, du sarcome et du cancer du rein et de l'estomac. De nombreuses études médicales montrent que 5 à 10 % des cancers courants sont considérés comme héréditaires. Des tests génétiques sont effectués pour déterminer si une personne est porteuse d'une variante génétique nocive. Ces tests permettent également de déterminer si un membre de la famille qui n'a pas encore eu de cancer a hérité de la même variante qu'un membre de la famille connu pour avoir une prédisposition au cancer.

Dynamique du marché européen des tests de dépistage du cancer héréditaire

Cette section traite de la compréhension des moteurs, des avantages, des opportunités, des contraintes et des défis du marché. Tout cela est discuté en détail ci-dessous :    

Conducteurs

• Incidence croissante du cancer héréditaire

Le cancer résulte de la croissance incontrôlée des cellules. Il est causé par des changements nocifs (mutations) dans les messages génétiques (gènes) qui contrôlent la croissance et la division des cellules, les empêchant de faire leur travail efficacement.

In hereditary cancer cases, the individual inherits a copy of the mutated growth regulatory gene from one parent and a working copy of the same gene from the other parent. The mutated gene is also called a "cancer susceptibility gene." As this cancer-susceptibility gene is inherited, it is found in every cell in the body, but a working copy of the gene keeps each cell functioning properly. However, if a mutation damages a functional copy of a gene in a cell, the cell can lose control of its growth and become cancerous. Thus, individuals who inherit a cancer gene are much more likely to develop certain cancers during their lifetime.

Thus, rising incidences of hereditary cancer increase the demand for hereditary cancer testing and may act as a driver for the growth of the Europe hereditary cancer testing market.

•  Increase In The Geriatric Population

Cancer can be a disease of aging patients. Across the globe, the geriatric population is increasing. The risk of hereditary cancer among geriatrics is much more. The rising geriatric population can result in better provision of the Europe hereditary cancer testing market. It anticipated an upsurge in demand in the Europe hereditary cancer testing market. An aging population is causing a redistribution of the demographic structure that will affect the future of health care. Undoubtedly, the risk of cancer increases exponentially with age.

Hereditary cancer, including its incidence and associated risk, using the world's largest complete family structure and medically confirmed cancer database, was approximately twice as high in the population aged 8-20 years born to affected parents or siblings of people who have no relatives. The risk of small bowel, testicular, thyroid, and bone cancers was five to eight times greater.

Thus, the increase in cancer incidences among the geriatric population is expected to be a driving factor for the growth of the Europe hereditary cancer testing market.

Restraint

• High Cost of Hereditary Cancer Testing

Hereditary cancer testing employs highly technologically advanced products. The development of these products involves rigorous research and development by the developing player. Thus, the procedures and product cost remains high, which proportionally increases the cost of testing. Testing kits are expensive because they are incredibly resource-intensive and involve high-paid doctors, transportation, and expensive medications.

• In addition, testing procedures have also been used in cancer testing. However, such procedures are very expensive and may be associated with complications and worse long-term outcomes.

Thus, the high cost of cancer testing using advanced modalities and technology products may be a major restraining factor for the growth of the Europe hereditary cancer testing market.

Opportunity

• Strategic Initiatives By Market Players

The rise in the Europe hereditary cancer testing market increases the need for strategic business ideas. It includes a partnership, business expansion, and other development. The surge in demand for hereditary cancer treatment is significantly increasing the demand for diagnostic testing methods. The planned strategies allow the market players to align with the organization's functional activities to achieve set goals. It guides the company's discussions and decision-making in determining resource and budget requirements to accomplish objectives, thus increasing operational efficiency.

These strategic initiatives, such as product launches, agreements, and business expansion by the major market players, will boost the market growth and are expected to act as an opportunity for the Europe hereditary cancer testing market. The strategic initiatives are expected to aid in growth and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players are expected to act as an opportunity for growth in the Europe hereditary cancer testing market.

Challenge

• Ethical Challenges Faced During Hereditary Cancer Testing

During hereditary cancer genetic testing, one of the significant ethical hindrances is health professionals' lack of basic knowledge about genetic testing and their lack of confidence in interpreting familial disease patterns. The challenge for healthcare providers is to provide sufficient information to support patient decision making-and evidence to support the reasoning behind any suggestions they might make.

The lack of reimbursement creates economic barriers to care. The process of hereditary cancer risk assessment and counseling is time-consuming, and it is unclear how best to document and bill for this service. Oncologists are often forced to navigate a potentially uncertain reimbursement environment for genetic testing, with various reimbursement policies among third-party payers.

Genetic testing for hereditary cancer elevates ethical matters, which can't be resolved with patients or their family members. The various aspects of ethical, cultural, and religious nature should not be a barrier to the act of hereditary cancer testing. All of these are issues to be solved. Therefore, ethical challenges during hereditary cancer testing are expected to challenge the market growth.

Post-COVID-19 Impact on Europe Hereditary Cancer Testing Market

Many industries around the world have been disadvantaged over the past 18 months. This could be due to the major disruptions that their industrial and supply chain processes are experiencing due to various precautionary measures such as shutdowns and other restrictions that the facilities around the world have been following. The same places the Europe hereditary cancer testing market. Also, consumption demand has subsequently decreased as people now have more opportunities to exclude non-essential expenses from their budgets as most people's overall finances have been severely affected by the boom. These aforementioned factors can be expected to burden the revenue margin of the Europe hereditary cancer testing market during the forecast period.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the transplant diagnostics market.

Recent Developments

• In July 2022, Helio Genomics and its business partner, Fulgent Genetics (FLGT) has announced that the American Medical Association (AMA) issued a new Category I Current Procedural Terminology (CPT) Proprietary Laboratory Analyses code for HelioLiver and broader adoption of advanced innovative surveillance tests for liver cancer in the U.S. This has helped the company to expand their product portfolio.
• In March 2022, Illumina, Inc. introduced the n vitro diagnostic (IVD) kit, a cancer RNA sequencer. The launch resulted in expansion of the sequencing product line, followed by post market approval.It is depicted to show a linear market growth.

Europe Hereditary Cancer Testing Market Scope

Europe hereditary cancer testing market is segmented into test type, diagnosis type, technology, disease type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

BY TEST TYPE

• MULTI PANEL TEST
• SINGLE SITE GENETIC TEST

On the basis of test type, the Europe hereditary cancer testing market is segmented into multi panel test and single site genetic test.

BY DIAGNOSIS TYPE

• BIOPSY
• IMAGING
• LAB TESTS

On the basis of diagnosis type, the Europe hereditary cancer testing market is segmented into biopsy, imaging, and lab tests.

BY TECHNOLOGY

• SEQUENCING
• POLYMERASE CHAIN REACTION (PCR)
• MICROARRAY

On the basis of technology, the Europe hereditary cancer testing market is segmented into sequencing, polymerase chain reaction (PCR), and microarray.

BY DISEASE TYPE

• HEREDITARY BREAST & OVARIAN CANCER SYNDROME
• COWDEN SYNDROME
• LYNCH SYNDROME
• HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROMES
• FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
• LI-FRAUMENI SYNDROME
• VON HIPPEL-LINDAU DISEASE
• MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROMES

On the basis of disease type, the Europe hereditary cancer testing market is segmented into hereditary breast & ovarian cancer syndrome, cowden syndrome, lynch syndrome, hereditary leukemia and hematologic malignancies syndromes, familial adenomatous polyposis (FAP), li-fraumeni syndrome, vol-hippel lindau disease, multiple endocrine neoplasias (MEN) syndrome.

 BY END USER

• HOSPITALS
• CLINICS
• LABORATORIES
• RADIOLOGY CENTERS 
• DIAGNOSTIC CENTERS
• OTHERS

On the basis of end user, the Europe hereditary cancer testing market is segmented into hospitals, clinics, laboratories, radiology centers, diagnostic centers, and others.

BY DISTRIBUTION CHANNEL

• DIRECT TENDER
• RETAIL SALES

On the basis of distribution channel, the Europe hereditary cancer testing market is segmented into direct tender, retail sales.

Europe Hereditary Cancer Testing Market Regional Analysis/Insights

The Europe hereditary cancer testing market is analyzed and market size information is provided by test type, diagnosis type, technology, disease type, end user, and distribution channel.

The countries covered in this market report Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and the rest of Europe.

• In 2022, Germany is expected to grow due to its advanced technology and inventions for the diagnosis of cancer.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Hereditary Cancer Testing Market Share Analysis

Europe hereditary cancer testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the Europe hereditary cancer testing market.

Some of the major players operating in the Europe hereditary cancer testing market are Invitae Corporation, Illumina, Inc., Natera, Inc., CENTOGENE N.V., 4baseCare, Biocartis, Fulgent Genetics, Ambry Genetics, BioReference, PerkinElmer Inc., LifeLabs, Abbott, BIO-HELIX, Cepheid, Eurofins Scientific, among others.

Research Methodology: Europe Hereditary Cancer Testing Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Europe vs Regional, and Vendor Share Analysis. Please request analyst call in case of further inquiry.

SKU-69431